EYPT Latest Headlines

DURAVYU’s Phase 3 LUGANO Results Reveal Compelling Efficacy and Reduced Treatment Burden in Wet AMD

Market Chameleon (Tue, 18-Aug 9:55 AM)

EyePoint Pharmaceuticals Sees Bold Insider Move From Boardroom

at www.tipranks.com (Tue, 18-Aug 10:09 PM)

Analyst Maintains Buy on Duravyu, Cutting Price Target to $20 Amid LUCIA Trial Binary Risk

at www.tipranks.com (Tue, 18-Aug 6:05 PM)

EyePoint rebounds after selloff despite multiple downgrades

at seekingalpha.com (Tue, 18-Aug 10:17 AM)

DURAVYU Reduces Wet AMD Treatment Burden by 42%: Phase 3 LUGANO Results Highlight Supplement-Free Durability

Market Chameleon (Mon, 17-Aug 7:06 AM)

EyePoint Wraps Up Phase 3 DURAVYU Enrollment Early, Signaling Strong Momentum for Diabetic Macular Edema Progress

Market Chameleon (Thu, 30-Jul 9:41 AM)